newsfilter
← Latest News
Business Wire·

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

FDA Also Approves and Closes RECOVER III Post-Approval Study Abiomed (NASDAQ:ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardi